drugset / Trial / NCT00611468
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Phase 1
Completed
29 enrolled
Accelerated Community Oncology Research Network
Genentech, Inc. · collabGlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the best dose of the combination of two approved drugs, intravenous topotecan and oral erlotinib.
Timeline
- Start
- 2006-06
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | Oral |
| Subject | Topotecan | Small molecule | — | Intravenous |